Based on the preclinical breast cancer results, we could anticipate melanoma FTO results by mid-late September 2021. This coincides with RAC management strategy of advertising preclinical program results to US smart money biotech investors at the later end of 2021.
Assuming the George Clinical scope and costing of a phase I/II proof of concept breast cancer clinic trial will land next week (18 weeks since announcement), we could also assume that a phase I/II FTO program could be scoped and costed by Feb 2022.
Conducting preclinical studies in animal models may push this estimation back, as well as other unforseen factors.
All IMO - DYOR
Ann: Race Initiates FTO Melanoma Preclinical Study, page-80
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |